Cetuximab is a human-mouse chimeric lgG1 monoclonal antibody (mAb) against EGFR, which specifically binds to EGFR and blocks the intracellular signaling pathway through the inhibition of tyrosine kinase binding to EGFR, thereby inhibiting the proliferation of cancer cells and inducing apoptosis (Raimúndez et al. 2020; Oda et al. 2005). Here, EGFR is linked to cancer.